Biovica International
UPPSALA, SE / ACCESSWIRE / September 14, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum ® TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.
The results from a large independent study with a CDK4/6 inhibitor therapy and DiviTum ® TKa as a treatment monitoring assay in 287 patients with metastatic breast cancer is presented at the ESMO congress.
"I'm happy to see that the presented results on this CDK4/6 inhibitor ribociclib are consistent with earlier CDK4/6-results for example for palbociclib. The study results are highly encouraging as a reference for using DiviTum®TKa for the monitoring of CDK4/6 inhibitor treatments in HR positive metastatic breast cancer," said Anders Rylander, CEO of Biovica.
The study concludes that TKa appears to be a new promising prognostic, predictive and monitoring biomarker in patients with HR positive/HER2 negative metastatic breast cancer treated with ribociclib plus letrozole as first-line therapy. Baseline and dynamic TKa changes provided independent valuable information. Lack of TKa suppression at day 15 indicates enrichment for primary resistance and poor prognosis. TKa rebound at treatment cycle 2, day 1 may indicate early adaptation to ribociclib plus letrozole, while persistent suppression seems to identify patients with sustained inhibition and excellent prognosis.
Link to poster: https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=292P+-+
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum ® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Promising DiviTumTKa results from BioItaLEE study presented at ESMO
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/663954/Promising-DiviTumTKa-Results-from-BioItaLEE-Study-Presented-at-ESMO
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Launches GoodData AI: Embed, Extend, and Scale Analytics with AI27.5.2025 08:30:00 CEST | Press release
AI-Native Analytics Platform That Understands Your Business - and Your Developers SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / GoodData today announced the general availability of GoodData AI, a next-generation analytics platform that places AI at every layer of the data stack - from raw-data ingestion to governed insight delivery - without compromising trust or compliance. Why GoodData AI Stands Apart GoodData AI is designed for enterprises that require trust, scalability, and extensibility. Its architecture is built around these foundational principles: Composable by design: Embedded, white-labeled, and API-first; built for developers to connect with any AI stack. Semantic layer and ontology: The only AI analytics engine that natively understands your business logic, ensuring every answer is both consistent and metric-perfect. Model Context Protocol (MCP) Support: Enables real-time, cross-system context that makes AI relevant. GoodData's new MCP Server Beta program is now ava
Affordable Mini LED with Premium Design - Meet the TCL C7K Series23.5.2025 04:40:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / May 23, 2025 / TCL, a global leader in consumer electronics and the world's No.1 Ultra-large, Mini LED, and Google TV brand, has introduced the C7K Series, a new series of 4K 144Hz QD-Mini LED TVs available in screen sizes ranging from 50" inches to 115" inches. The C7K delivers advanced backlight control, high brightness performance and immersive audio technology at pricing that challenges conventional premium categories. The C7K Series is designed for those who demand more from their screen-whether that's sharper gaming, immersive movie nights, or simply an ultra-vivid sports match. Featuring QD-Mini LED technology and TCL's Precise Dimming Series, the C7K boasts up to 2880 dimming zones on the 115" model, offering deeper blacks, contrast and colour gamut levels comparable to OLED , while also providing higher peak brightness and a longer lifespan. HDR Premium 3000 and 144Hz Motion Clarity Visual performance is driven by HDR Premium 3000, ca
TCL Brings Premium Mini LED TV to More Homes with Amazon Brand Week Savings23.5.2025 04:40:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / May 23, 2025 / This Amazon Brand Week (26 th May - 1 st June), TCL invites consumers to upgrade their home entertainment with exclusive offers on its latest Mini LED TV series, the 2025 Q6C-UK series. Whether you're planning a summer of sports, immersive movie nights, or epic gaming sessions, these limited-time deals make premium TV technology more accessible than ever. With cutting-edge features and limited promotional pricing, there's never been a better time to bring a cinematic experience into your living room.t. At the heart of the 2025 Q-Series is TCL's next-generation QD-Mini LED technology , combining the best of QLED and OLED for pixel-level lighting precision. The advanced Quantum Dot Pro and Mini LED backlight system deliver stunning contrast, ultra-high peak brightness , and a wider colour gamut - bringing vivid colours and striking realism to every scene. With up to 512 dimming zones (on the 98" Q6C-UK model), viewers enjoy deeper
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent23.5.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO‘s intention to grant BioNxt its core patent without significant changes. The Company's core patent filing was a comprehensive application for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS). "Confirmation of the Company's flagship intellectual property asset in Europe is a major milestone for BioNxt," stated Hugh Rogers, CEO of BioNxt. "We expect the European paten
DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis22.5.2025 07:56:00 CEST | Press release
Innovative Asset Monitoring Technology Selected by U.S.'s Largest Container Chassis Provider WATERLOO, ON / ACCESS Newswire / May 22, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that Direct ChassisLink, Inc. ("DCLI"), the largest provider of container chassis to the U.S. intermodal industry, will deploy BlackBerry® Radar® across 100,000 of its DCL53 domestic 53-foot chassis. The rollout is part of a major initiative DCLI is undertaking to enhance the quality, reliability, visibility and operational efficiency of its fleet, with a view to setting a new freight industry standard for data driven decision-making. The deployment represents a deepening in the companies' technological collaboration. DCLI has utilized Radar devices on a subset of its fleet for over five years and after seeing the reliability and intelligence they provide, decided to exponentially increase the number of its chassis deployed with the solution while also recognizing Radar as a top tier supplier. W
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom